Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors

CHUN-TA HUANGLin, Chih-AnChih-AnLinSu, Te-JenTe-JenSuCHING-YAO YANGTZU-HSIU TSAICHIA-LIN HSUWEI-YU LIAOKUAN-YU CHENCHAO-CHI HOCHONG-JEN YU2023-04-202023-04-202023-03-131471-2407https://scholars.lib.ntu.edu.tw/handle/123456789/630363The T790M mutation is the major resistance mechanism to first- and second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet digital PCR (ddPCR) for detection of T790M in plasma circulating tumor DNA (ctDNA), and explore its impact on prognosis.enDroplet digital polymerase chain reaction; EGFR mutation; Lung cancer; Osimertinib; Tyrosine kinase inhibitor[SDGs]SDG3Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitorsjournal article10.1186/s12885-023-10698-5369151012-s2.0-85150089969WOS:000949208400002https://api.elsevier.com/content/abstract/scopus_id/85150089969